S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
NASDAQ:NBIX

Neurocrine Biosciences Stock Forecast, Price & News

$78.36
-0.86 (-1.09%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$77.21
$80.63
50-Day Range
$75.32
$93.57
52-Week Range
$71.88
$120.27
Volume
929,760 shs
Average Volume
1.11 million shs
Market Capitalization
$7.43 billion
P/E Ratio
17.15
Dividend Yield
N/A
Beta
0.74
30 days | 90 days | 365 days | Advanced Chart
Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Neurocrine Biosciences logo

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Headlines

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $103.00
January 7, 2022 |  americanbankingnews.com
Expert Ratings For Neurocrine Biosciences
December 8, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
845
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$4.66 per share
Book Value
$11.99 per share

Profitability

Net Income
$407.30 million
Pretax Margin
14.67%

Debt

Price-To-Earnings

Miscellaneous

Free Float
90,788,000
Market Cap
$7.43 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/01/2021
Today
1/17/2022
Next Earnings (Estimated)
2/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.73 out of 5 stars

Medical Sector

52nd out of 1,405 stocks

Biological Products, Except Diagnostic Industry

6th out of 206 stocks

Analyst Opinion: 4.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

Is Neurocrine Biosciences a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 1 sell rating, 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Neurocrine Biosciences stock.
View analyst ratings for Neurocrine Biosciences
or view top-rated stocks.

How has Neurocrine Biosciences' stock price been impacted by Coronavirus?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBIX shares have decreased by 8.8% and is now trading at $78.36.
View which stocks have been most impacted by COVID-19
.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Neurocrine Biosciences
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Monday, November, 1st. The company reported $0.23 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.51 by $0.28. The company earned $296 million during the quarter, compared to analysts' expectations of $297.02 million. Neurocrine Biosciences had a net margin of 41.59% and a trailing twelve-month return on equity of 35.89%. The business's revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.62) earnings per share.
View Neurocrine Biosciences' earnings history
.

What price target have analysts set for NBIX?

17 Wall Street analysts have issued twelve-month price objectives for Neurocrine Biosciences' stock. Their forecasts range from $76.00 to $154.00. On average, they anticipate Neurocrine Biosciences' share price to reach $117.57 in the next twelve months. This suggests a possible upside of 50.0% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:
  • Kevin Charles Gorman, Chief Executive Officer & Director
  • Bill Wilson, Vice President-Information Technology & Operations
  • Matthew C. Abernethy, Chief Financial Officer
  • Dimitri E. Grigoriadis, Chief Research Officer
  • Eiry W. Roberts, Chief Medical Officer

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Square (SQ) and salesforce.com (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.26%), DNB Asset Management AS (0.15%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.01%), Red Spruce Capital LLC (0.01%) and Exchange Traded Concepts LLC (0.01%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences
.

Which institutional investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Crossmark Global Holdings Inc., and State of Alaska Department of Revenue. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, and Matt Abernethy.
View insider buying and selling activity for Neurocrine Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, First Hawaiian Bank, Exchange Traded Concepts LLC, Stonnington Group LLC, Red Spruce Capital LLC, and Louisiana State Employees Retirement System.
View insider buying and selling activity for Neurocrine Biosciences
or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $78.36.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences has a market capitalization of $7.43 billion and generates $1.05 billion in revenue each year. The company earns $407.30 million in net income (profit) each year or $4.57 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

Neurocrine Biosciences employs 845 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

Where are Neurocrine Biosciences' headquarters?

Neurocrine Biosciences is headquartered at 12780 EL CAMINO REAL, SAN DIEGO CA, 92130.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 617-7600, via email at [email protected], or via fax at 858-617-7602.


This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.